In last trading session, Cartesian Therapeutics Inc (NASDAQ:RNAC) saw 0.34 million shares changing hands with its beta currently measuring 0.50. Company’s recent per share price level of $10.00 trading at -$2.34 or -18.96% at ring of the bell on the day assigns it a market valuation of $259.07M. That closing price of RNAC’s stock is at a discount of -318.7% from its 52-week high price of $41.87 and is indicating a discount of -16.6% from its 52-week low price of $11.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 97850.0 shares which gives us an average trading volume of 83.05K if we extend that period to 3-months.
Cartesian Therapeutics Inc (NASDAQ:RNAC) trade information
Upright in the red during last session for losing -18.96%, in the last five days RNAC remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $10.00 price level, adding 30.8% to its value on the day. Cartesian Therapeutics Inc’s shares saw a change of -44.17% in year-to-date performance and have moved -31.22% in past 5-day. Cartesian Therapeutics Inc (NASDAQ:RNAC) showed a performance of -43.98% in past 30-days. Number of shares sold short was 2.03 million shares which calculate 25.39 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 43 to the stock, which implies a rise of 76.74% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -300.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -300.0% for stock’s current value.
Cartesian Therapeutics Inc (RNAC) estimates and forecasts
This year revenue growth is estimated to fall -92.93% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 687.5k for the same. And 8 analysts are in estimates of company making revenue of 687.5k in the next quarter. Company posted 5.84M and 33.45M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.24% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 32.10% while estimates for its earnings growth in next 5 years are of 0.19%.
Cartesian Therapeutics Inc (NASDAQ:RNAC)’s Major holders
Insiders are in possession of 59.28% of company’s total shares while institution are holding 26.66 percent of that, with stock having share float percentage of 65.48%. Investors also watch the number of corporate investors in a company very closely, which is 26.66% institutions for Cartesian Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RNAC for having 0.51 million shares of worth $13.8 million. And as of 2024-06-30, it was holding 0.3293 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 0.41 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.2628 of outstanding shares, having a total worth of $11.01 million.
On the other hand, Fidelity Select Portfolios-Biotechnology Portfolio and Fidelity Select Portfolios-Health Care Portfolio are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 766.75 shares of worth $7.67 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 368.99 shares on Feb 28, 2025 , making its stake of worth around $3.69 million in the company or a holder of 1.42% of company’s stock.
